Mindfulness-Based Cognitive Therapy Excels in Episodic Migraine
July 11th 2019As measured with the Migraine Disability Assessment, the proportion of patients with episodic migraine experiencing severe disability was reduced significantly, and Headache Disability Inventory scores were significantly reduced.
Kelly Knupp, MD: Keeping Perspective on CBD for Pediatric Epilepsies
July 10th 2019The pediatric neurologist and epilepsy specialist at Children’s Hospital Colorado spoke about the need to continue to research therapies once they’re approved to better understand their use, and how cannabidiol falls into this category.
Michael Sperling, MD: Surgical Advancements for Epilepsy
July 9th 2019The director of the Jefferson Comprehensive Epilepsy Center spoke about the improvements that have come along with some of the surgical advancements in the treatment of epilepsy, specifically with laser interstitial thermal ablation.
Sharon Chiang, MD, PhD: Recording Seizures With Detection Technology
July 8th 2019The neurology resident at the University of California San Francisco discussed how new wearable technology and electronic diaries have helped improve the understanding of seizure rhythmicity, and ultimately, epilepsy care.
Improving Epilepsy Care By Systematically Measuring Seizure Rhythmicity
July 5th 2019In order to improve patient care in epilepsy, physicians need a more consistent and cohesive method of recording patient seizure activity. As wearables get more sensitive and specific, using them in tandem with electronic seizure diaries may help address the challenge.
Marisa McGinley, DO: Advantages of Outpatient Telemedicine in Neurology Subspecialties
July 5th 2019The staff neurologist at Cleveland Clinic’s Mellen Center for MS shared her insight into the use of telemedicine in an outpatient setting across a number of subspecialties in neurology and how it can supplement care going forward.
Making MS Therapy Decisions in an Ever-Evolving Treatment Landscape
July 4th 2019The MS neurologist at Cleveland Clinic’s Lou Ruvo Center for Brain Health discussed the impact that propensity score has had on real-world data analysis, the use of additional outcome measures in trials, and the increasing understanding of progressive disease.
Brian J. Murray, MD: Establishing Normal Values in Polysomnography
July 3rd 2019The head of neurology at the Sunnybrook Health Sciences Centre of the University of Toronto spoke about the limited available normative sleep data, and shared insight into the findings of the meta-analysis he and colleagues conducted of more than 150 studies.
Sharon Chiang, MD, PhD: The Usefulness of Seizure Diaries in Epilepsy
July 2nd 2019The neurology resident at the University of California San Francisco spoke about the role that seizure diaries can play in a patient’s peace of mind, as well as in the understanding of that patient’s response to a given treatment.
In Intractable Epilepsy, Rufinamide is Well-Tolerated and Effective
June 26th 2019Data suggest that rufinamide is capable of aiding in the control and reduction of seizures, as well as the possible achievement of seizure-freedom in pediatric patients with genetic/metabolic, hypoxic-ischemic, structural, and other intractable epilepsies.
Sanjeev V. Thomas, MD, DM: Managing Epilepsy During Pregnancy
June 26th 2019The chief of neurology at Sree Chitra Tirunal Institute for Medical Sciences and Technology spoke about how to reassure patients with epilepsy who are planning for pregnancy and how to make treatment decisions with pregnant patients.
Hannah Cock, MD, MBBS: Challenges in Treating Status Epilepticus
June 25th 2019The professor of epilepsy and medical education at St. George’s University Hospital London spoke about the number of challenges plaguing epileptologists when treating patients who present with possible status epilepticus in the hospital.
Perampanel Does Not Worsen Myoclonic or Absence Seizures in Patients With Epilepsy
June 24th 2019Overall, myoclonic and absence seizures worsened in 1.2% and 15.9% more patients in the placebo group, respectively, than those given perampanel. The reductions in seizure frequency and the increases in seizure-free days were also greater with the noncompetitive AMPA receptor antagonist.
Perampanel Monotherapy Promotes Seizure Freedom in Previously Untreated Partial Onset Epilepsy
June 23rd 2019Preliminary results from the 4 mg maintenance period of the FREEDOM study, the first in which perampanel has been examined as monotherapy, were presented at the 2019 International Epilepsy Congress in Bangkok.